JP6511430B2 - がんの治療のための化合物および組成物 - Google Patents
がんの治療のための化合物および組成物 Download PDFInfo
- Publication number
- JP6511430B2 JP6511430B2 JP2016501185A JP2016501185A JP6511430B2 JP 6511430 B2 JP6511430 B2 JP 6511430B2 JP 2016501185 A JP2016501185 A JP 2016501185A JP 2016501185 A JP2016501185 A JP 2016501185A JP 6511430 B2 JP6511430 B2 JP 6511430B2
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- mmol
- compound
- nmr
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361776520P | 2013-03-11 | 2013-03-11 | |
| US61/776,520 | 2013-03-11 | ||
| PCT/US2014/023263 WO2014164704A2 (en) | 2013-03-11 | 2014-03-11 | Compounds and compositions for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016512520A JP2016512520A (ja) | 2016-04-28 |
| JP2016512520A5 JP2016512520A5 (enExample) | 2017-04-13 |
| JP6511430B2 true JP6511430B2 (ja) | 2019-05-15 |
Family
ID=50729763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501185A Active JP6511430B2 (ja) | 2013-03-11 | 2014-03-11 | がんの治療のための化合物および組成物 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9890127B2 (enExample) |
| EP (1) | EP2970145B1 (enExample) |
| JP (1) | JP6511430B2 (enExample) |
| WO (1) | WO2014164704A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI621434B (zh) * | 2014-10-24 | 2018-04-21 | 朗齊生物醫學股份有限公司 | 千憂解藥物應用於癌症治療 |
| CN104478809B (zh) * | 2014-11-14 | 2016-08-17 | 成都新恒创药业有限公司 | 一种左西孟旦杂质及其制备和检测方法 |
| AU2015370666B2 (en) | 2014-12-22 | 2020-09-03 | Arovella Therapeutics Limited | Prevention and treatment of metastatic disease in thrombocytotic cancer patients |
| HUE057041T2 (hu) | 2015-07-06 | 2022-04-28 | Alkermes Inc | Hiszton deacetiláz hetero-halogén gátlói |
| WO2017007755A1 (en) | 2015-07-06 | 2017-01-12 | Rodin Therapeutics, Inc. | Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase |
| WO2017027854A1 (en) * | 2015-08-13 | 2017-02-16 | The Broad Institute, Inc. | Compositions and methods for cancer expressing pde3a or slfn12 |
| TW201733591A (zh) | 2016-02-05 | 2017-10-01 | 拜耳製藥公司 | 用於癌症病人分級及癌症治療之化合物、組合物及方法 |
| BR112017021277A2 (pt) * | 2016-02-08 | 2018-06-26 | H Lundbeck As | Síntese de 1-[2-(2,4-dimetil-fenilsulfanil)-fenil] piperazina |
| MY196801A (en) | 2016-03-04 | 2023-05-03 | Otsuka Pharma Co Ltd | 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative |
| CN109153644B (zh) | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| CN105968054B (zh) * | 2016-05-12 | 2018-09-14 | 海门慧聚药业有限公司 | 匹莫苯丹关键中间体的制备 |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| US11142522B2 (en) | 2017-02-03 | 2021-10-12 | The Broad Institute, Inc. | Compounds, compositions and methods for cancer treatment |
| EP3661917B1 (en) * | 2017-08-04 | 2022-05-11 | Bayer Aktiengesellschaft | 6-((3-trifluoromethyl)phenyl)-4,5-dihydropyridazin-3(2h)-one derivatives as pde3a and pde3b inhibitors for treating cancer |
| JOP20200024A1 (ar) | 2017-08-04 | 2020-02-02 | Bayer Ag | مركبات ثنائي هيدروكساديازينون |
| US11225475B2 (en) | 2017-08-07 | 2022-01-18 | Alkermes, Inc. | Substituted pyridines as inhibitors of histone deacetylase |
| JP7104588B2 (ja) * | 2017-09-01 | 2022-07-21 | 大塚製薬株式会社 | ５－メチル－６－フェニル－４，５－ジヒドロ－２ｈ－ピリダジン－３－オン誘導体を含有する悪性腫瘍治療剤 |
| CN110117257B (zh) * | 2018-02-05 | 2022-12-06 | 安徽省新星药物开发有限责任公司 | 一种含胍基的p2y12受体拮抗剂、制备方法及其用途 |
| CN108997349B (zh) * | 2018-06-20 | 2021-03-16 | 合肥华方医药科技有限公司 | 一种依匹斯汀有关物质的制备方法 |
| EP3820532A4 (en) | 2018-07-11 | 2022-04-06 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | DIMERE IMMUNOMODULATORY COMPOUNDS AGAINST CEREBLON-BASED MECHANISMS |
| WO2020157188A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Dihydrooxadiazinones for the treatment of hyperproliferative diseases |
| WO2020157199A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Annulated dihydropyridazinone compounds as anti-cancer compounds |
| AU2020215088A1 (en) | 2019-02-01 | 2021-07-22 | Bayer Aktiengesellschaft | 1,2,4-triazin-3(2H)-one compounds for the treatment of hyperproliferative diseases |
| WO2020157201A1 (en) * | 2019-02-01 | 2020-08-06 | Bayer Aktiengesellschaft | Oxadiazinone compounds for the treatment of hyperproliferative diseases |
| CN113582974B (zh) * | 2020-04-30 | 2022-05-17 | 江西济民可信集团有限公司 | 一类作为蛋白降解剂的化合物及其制备方法和医药用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2624730A (en) * | 1950-08-16 | 1953-01-06 | Sterling Drug Inc | 6-haloaryl-3-pyridazones |
| SE352811B (enExample) | 1971-06-04 | 1973-01-15 | Pharmacia Ab | |
| US3960150A (en) | 1971-09-09 | 1976-06-01 | Alza Corporation | Bioerodible ocular device |
| US3867519A (en) | 1972-04-27 | 1975-02-18 | Alza Corp | Bioerodible drug delivery device |
| US3824271A (en) | 1972-07-20 | 1974-07-16 | American Cyanamid Co | 3-alkyl-3-(benzoyl)propionitriles |
| SE375007B (enExample) | 1972-11-30 | 1975-04-07 | Pharmacia Ab | |
| US3963025A (en) | 1974-09-16 | 1976-06-15 | Alza Corporation | Ocular drug delivery device |
| US4052395A (en) | 1975-09-11 | 1977-10-04 | Sankyo Company Limited | Agricultural fungicidal compositions containing 6-(substituted phenyl)-pyridazinones and said pyridazinones |
| US4092311A (en) | 1976-06-03 | 1978-05-30 | American Cyanamid Company | Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates |
| US4186184A (en) | 1977-12-27 | 1980-01-29 | Alza Corporation | Selective administration of drug with ocular therapeutic system |
| US4303637A (en) | 1980-04-04 | 1981-12-01 | Alza Corporation | Medication indicated for ocular hypertension |
| DE3263497D1 (en) * | 1981-03-04 | 1985-06-20 | Ciba Geigy Ag | Pyridazinones, method for their preparation, pharmaceutical compositions containing these compounds and their use |
| US4717730A (en) * | 1982-12-03 | 1988-01-05 | Warner-Lambert Company | 4,5-dihydro-6-(substituted)phenyl-5-methyl-3-(2H)-pyridazinones and pharmaceutical compositions containing the compounds as active components |
| JPS6061570A (ja) | 1983-09-16 | 1985-04-09 | Sankyo Co Ltd | ピリダジノン誘導体及び農業用殺菌剤 |
| JPS6153270A (ja) * | 1984-08-17 | 1986-03-17 | チバ・ガイギー・アクチエンゲゼルシヤフト | 置換ピリダジノン、その製造方法及び該化合物を含む医薬製剤 |
| GB8426804D0 (en) * | 1984-10-23 | 1984-11-28 | Ciba Geigy Ag | Pyridazinones preparations |
| DE3531658A1 (de) | 1985-09-05 | 1987-03-12 | Boehringer Mannheim Gmbh | Heterocyclisch substituierte indole, zwischenprodukte, verfahren zu ihrer herstellung und arzneimittel |
| DE3804490A1 (de) * | 1988-02-12 | 1989-08-24 | Heumann Pharma Gmbh & Co | Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5053338A (en) * | 1989-09-01 | 1991-10-01 | Glaxo Inc. | Kinetic resolution of pyridazinones using lipase |
| GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
| JPH05140116A (ja) | 1991-11-21 | 1993-06-08 | Nippon Soda Co Ltd | 光学活性な化合物 |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| CA2204915A1 (en) | 1994-11-11 | 1996-05-23 | Seiichi Uchida | Optically active compound |
| US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
| US6525053B1 (en) * | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
| EP2502918B1 (en) * | 2006-07-25 | 2015-03-25 | Cephalon, Inc. | Pyridazinone Derivatives |
| JP2010013354A (ja) * | 2006-09-07 | 2010-01-21 | Kyorin Pharmaceut Co Ltd | ２−アルキル−６−（ピラゾロピリジン−４−イル）ピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| CN101538245B (zh) * | 2008-03-18 | 2011-02-16 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和制备药物的用途 |
-
2014
- 2014-03-11 WO PCT/US2014/023263 patent/WO2014164704A2/en not_active Ceased
- 2014-03-11 US US14/775,354 patent/US9890127B2/en active Active
- 2014-03-11 JP JP2016501185A patent/JP6511430B2/ja active Active
- 2014-03-11 EP EP14724186.3A patent/EP2970145B1/en active Active
-
2018
- 2018-01-18 US US15/874,500 patent/US20180244629A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016512520A (ja) | 2016-04-28 |
| WO2014164704A2 (en) | 2014-10-09 |
| WO2014164704A3 (en) | 2014-12-31 |
| US20180244629A1 (en) | 2018-08-30 |
| US20160016913A1 (en) | 2016-01-21 |
| EP2970145A2 (en) | 2016-01-20 |
| US9890127B2 (en) | 2018-02-13 |
| EP2970145B1 (en) | 2020-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2970145B1 (en) | Compounds and compositions for the treatment of cancer | |
| KR102218333B1 (ko) | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 | |
| AU2014298051B2 (en) | Novel quinazolinones as bromodomain inhibitors | |
| JP3649395B2 (ja) | 縮合ヘテロアリール誘導体 | |
| RU2686323C2 (ru) | Новые соединения и композиции для ингибирования fasn | |
| KR100737090B1 (ko) | 축합 이미다졸륨 유도체 | |
| JP7788208B2 (ja) | キナーゼネットワークの阻害剤およびその使用 | |
| BR112014015720B1 (pt) | Derivados de tieno[3,2-d]pirimidina, composição farmacêutica e uso dos mesmos para a prevenção ou tratamento de uma doença causada por ativação anormal de uma proteína quinase | |
| JPWO2020017587A1 (ja) | ピリダジノン誘導体 | |
| TW201927792A (zh) | 作為溴結構域蛋白質抑制劑的化合物和組合物 | |
| BR122023004130B1 (pt) | Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1 | |
| BR112013002375B1 (pt) | Composto, processo de preparação do mesmo, composição farmacêutica, e, usos de um composto | |
| JP2013530951A (ja) | ヤヌスキナーゼ阻害剤としてのヘテロ環式化合物 | |
| TW201910329A (zh) | 取代五元并六元雜環類化合物、其製備方法、藥物組合及其用途 | |
| WO2014159938A1 (en) | Substituted aminothiazoles for the treatment of tuberculosis | |
| WO2022199676A1 (zh) | 稠合四环类化合物、其制备方法及其在医药上的应用 | |
| CN114105977A (zh) | 雌激素受体调节剂化合物及其用途 | |
| BR112017004035B1 (pt) | Inibidores macrocíclicos de rip2 quinase e composições farmacêuticas | |
| TW202043209A (zh) | Mek抑制劑及其在醫藥上的應用 | |
| CN105367472B (zh) | 吲哚啉类衍生物及其在药物上的应用 | |
| TW206230B (enExample) | ||
| JP7175878B2 (ja) | 新規ベンズイミダゾロン化合物およびその医薬用途 | |
| JP2023536442A (ja) | オキサアザスピロ環系誘導体、その調製方法及びその医薬的応用 | |
| CN106045967B (zh) | 取代杂环化合物及其在药物上的应用 | |
| WO2021039961A1 (ja) | 縮環ピラゾール誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170310 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170310 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180109 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180403 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180608 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180904 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190109 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190305 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190401 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190408 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6511430 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |